Thompson Davis & Co’s ProQR Therapeutics PRQR Stock Holding History

Thompson Davis & Co’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-2,000	Closed	-$10K	–	978
2017 Q3	$10K	Buy	+2,000	New	+$10.4K	0.02%	691

Other funds holding PRQR

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

Thompson Davis & Co's PRQR Position: Q4 2017 in Review

Thompson Davis & Co sold out of ProQR Therapeutics (PRQR) in Q4 2017, closing a stake of 2,000 shares — an estimated $10K sold.

Thompson Davis & Co first reported a position in PRQR in Q3 2017 and held it in 1 quarter. The position peaked at $10K in Q3 2017. 27 funds tracked by Wall St. Rank hold PRQR as of Q4 2017.

Thompson Davis & Co reported no remaining ProQR Therapeutics position as of Q4 2017 after selling out during the quarter.
Thompson Davis & Co sold 2,000 ProQR Therapeutics shares in Q4 2017, an estimated $10K.
Thompson Davis & Co first reported a position in ProQR Therapeutics in Q3 2017 and held it in 1 quarter.
Thompson Davis & Co's ProQR Therapeutics position peaked at $10K in Q3 2017.
27 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.